GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California. Show more

Location: 2223 Avenida de la Playa, LA Jolla, CA, 92037, United States | Website: https://www.gribio.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

3.896M

52 Wk Range

$1.10 - $43.69

Previous Close

$1.58

Open

$1.55

Volume

187,110

Day Range

$1.53 - $1.70

Enterprise Value

-410.5K

Cash

3.281M

Avg Qtr Burn

-2.036M

Insider Ownership

0.02%

Institutional Own.

0.21%

Qtr Updated

03/31/25

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
ADAIR (proprietary abuse-deterrent formulation of immediate-release) Details Attention deficit hyperactivity disorder	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GRI-0621 Details Idiopathic pulmonary fibrosis	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
GRI-0803 Details Autoimmune disease, Systemic lupus erythematosus	IND Submission	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.